No one will accuse Valeant (NYSE: VRX )
CEO Mike Pearson of lacking boldness. He has laid out a strategy for
turning Valeant into one of the largest pharmaceutical/med-tech
companies in the world and has proven more than willing to turn to bold
M&A moves to make it happen. Valeant's latest move is far and away
the largest – a $47 billion bid (at the time of the offer) for Allergan (NYSE: AGN )
– but the target's acceptance is hardly a sure thing and the company's
views about the pharma industry may give investors reason for pause
regarding the long-term strategy.
Read the full article here:
Can Allergan Find an Alternative To Valeant?
No comments:
Post a Comment